MARC Record from marc_columbia

LEADER: 06332mam a22005294a 4500
001 3350142
005 20221020050324.0
008 020403t20032003njua b 001 0 eng c
010 $a 2002067889
016 7 $a101142245$2DNLM
020 $a0896039188 (alk. paper)
035 $a(OCoLC)ocm49576679
035 $9AVA6909CU
035 $a3350142
040 $aDNLM/DLC$cDLC$dNLM$dC#P$dOrLoB-B
042 $apcc
050 00 $aRC271.I45$bR43 2003
060 10 $aW1$bME9616J v.207 2003
060 10 $aQZ 266$bR311 2003
082 00 $a616.99/4061$221
245 00 $aRecombinant antibodies for cancer therapy :$bmethods and protocols /$cedited by Martin Welschof and Jürgen Krauss.
260 $aTotowa, N.J. :$bHumana Press,$c[2003], ©2003.
300 $axiv, 481 pages :$billustrations ;$c24 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
490 1 $aMethods in molecular biology ;$vv. 207
504 $aIncludes bibliographical references and index.
505 00 $gPt. I.$tIntroduction.$g1.$tGeneration of Antibody Molecules Through Antibody Engineering /$rSergey M. Kipriyanov.$g2.$tApplication of Recombinant Antibodies in Cancer Patients /$rJurgen Krauss, Michaela Arndt and Michael Pfreundschuh --$gPt. II.$tHybridoma-Derived Antibodies.$g3.$tDNA Immunization as a Means to Generate Antibodies to Proteins /$rPartha S. Chowdhury.$g4.$tChimerization of a Monoclonal Antibody for Treating Hodgkin's Lymphoma /$rJurgen Krauss, Hans Heinrich Forster, Barbara Uchanska-Ziegler and Andreas Ziegler.$g5.$tHumanization of Monoclonal Antibodies by CDR Grafting /$rSiobhan O'Brien and Tarran Jones --$gPt. III.$tRecombinant Antibody Fragments from Phagemid-Displayed Antibody Repertoires.$g6.$tGeneration and Screening of a Modular Human scFv Expression Library from Multiple Donors /$rMartin Welschof, Christiane Christ, Ingrid Hermes, Armin Keller, Christian Kleist and Michael Braunagel.$g7.$tConstruction of Semisynthetic Antibody Libraries /$rMichael Braunagel.
505 80 $g8.$tSingle-Domain V[subscript H] Antibody Fragments from a Phage Display Library /$rLiat Binyamin, Daniel Plaksin and Yoram Reiter.$g9.$tIsolation of Human Fab Fragments Against Ovarian Carcinoma Using Guided Selection /$rMariangela Figini, Andrew Green, Francesco Colotta and Silvana Canevari.$g10.$tHuman Recombinant Fab Antibodies with T-Cell Receptor-Like Specificities Generated from Phage Display Libraries /$rJan Engberg, Ali F. Venidunya, Rikke Clausen, Liselotte B. Jensen, Peter Sorensen, Pernille Kops and Erik Riise.$g11.$tEngineering Hot Spots for Affinity Enhancement of Antibodies /$rPartha S. Chowdhury.$g12.$tSimultaneous Humanization and Affinity Optimization of Monoclonal Antibodies /$rHerren Wu.$g13.$tTailoring Kinetics of Antibodies Using Focused Combinatorial Libraries /$rHerren Wu and Ling-Ling An --$gPt. IV.$tAntibody Fragments with Additional Properties.$g14.$tEngineering scFvs for Improved Stability /$rPartha S. Chowdhury and George Vasmatzis.
505 80 $g15.$tRecombinant Single-Chain and Disulfide-Stabilized Fv Immunotoxins for Cancer Therapy /$rRavital Niv, Dina Segal and Yoram Reiter.$g16.$tGeneration of Recombinant Immunotoxins for Specific Targeting of Tumor-Related Peptides Presented by MHC Molecules /$rCyril J. Cohen, Galit Denkberg, Dina Segal and Yoram Reiter.$g17.$tConstruction and Characterization of RNase-Based Targeted Therapeutics /$rDianne L. Newton, Junichiro Futami, Dale Ruby and Susanna M. Rybak.$g18.$tBispecific Diabodies for Cancer Therapy /$rMichaela Arndt and Jurgen Krauss.$g19.$tGeneration and Characterization of Bispecific Tandem Diabodies for Tumor Therapy /$rSergey M. Kipriyanov.$g20.$tGeneration of Recombinant Multimeric Antibody Fragments for Tumor Diagnosis and Therapy /$rBarbara E. Power, Alexander A. Kortt and Peter J. Hudson.$g21.$tConstruction and Characterization of Minibodies for Imaging and Therapy of Colorectal Carcinomas /$rPaul J. Yazaki and Anna M. Wu.
505 80 $g22.$tGeneration, Expression, and Monitoring of Recombinant Immune Receptors for Use in Cellular Immunotherapy /$rAndreas Hombach, Claudia Heuser and Hinrich Abken.$g23.$tTailoring Natural Effector Functions: Antibody Engineering Beyond Humanization /$rOle H. Brekke and John E. Thommesen.$g24.$tSingle-Chain Fv-Based Affinity Purification of the Cellular Stress Protein gp96 for Vaccine Development /$rChristian Kleist, Daniele Arnold-Schild, Martin Welschof, Martina Finger, Gerhard Opelz, Hans-Georg Rammensee, Hansjorg Schild and Peter Terness.$g25.$tRecombinant Adenoviruses for In Vivo Expression of Antibody Fragments /$rRoland E. Kontermann, Tina Korn and Valerie Jerome --$gPt. V.$tLarge Scale Production of Recombinant Antibodies for Clinical Application.$g26.$tProduction of Antibody Fragments in a Bioreactor /$rHalldis Hellebust.$g27.$tLarge Scale Production of Recombinant Antibodies by Utilizing Cellulose-Binding Domains /$rItai Benhar and Yevgeny Berdichevsky.
505 80 $g28.$tProduction of Tumor-Specific Antibodies in Tobacco /$rCarmen Vaquero-Martin and Rainer Fischer.
650 0 $aCancer$xImmunotherapy.$0http://id.loc.gov/authorities/subjects/sh87002642
650 0 $aRecombinant antibodies$vLaboratory manuals.
650 12 $aAntibodies$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D000906Q000627
650 12 $aNeoplasms$xtherapy.$0https://id.nlm.nih.gov/mesh/D009369Q000628
650 22 $aAntibodies$ximmunology.$0https://id.nlm.nih.gov/mesh/D000906Q000276
650 22 $aAntigens, Neoplasm$ximmunology.$0https://id.nlm.nih.gov/mesh/D000951Q000276
650 22 $aAntineoplastic Protocols.$0https://id.nlm.nih.gov/mesh/D024221
650 22 $aImmunoglobulin Fragments$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D007128Q000627
650 22 $aImmunotherapy$xmethods.$0https://id.nlm.nih.gov/mesh/D007167Q000379
650 22 $aNeoplasms$ximmunology.$0https://id.nlm.nih.gov/mesh/D009369Q000276
650 22 $aRecombinant Proteins$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D011994Q000627
700 1 $aWelschof, Martin.$0http://id.loc.gov/authorities/names/n2002133973
700 1 $aKrauss, Jürgen.$0http://id.loc.gov/authorities/names/n2002133974
830 0 $aMethods in molecular biology (Clifton, N.J.) ;$vv. 207.$0http://id.loc.gov/authorities/names/n92002874
852 00 $boff,bio$hRC271.I45$iR43 2003